Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin最新文献

{"title":"High antimicrobial resistance in urinary tract infections in male outpatients in routine laboratory data, Germany, 2015 to 2020.","authors":"Jonas Salm,&nbsp;Florian Salm,&nbsp;Patricia Arendarski,&nbsp;Tobias Siegfried Kramer","doi":"10.2807/1560-7917.ES.2022.27.30.2101012","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.30.2101012","url":null,"abstract":"<p><p>BackgroundEvidence on the distribution of bacteria and therapy recommendations in male outpatients with urinary tract infections (UTI) remains insufficient.AimWe aimed to report frequency distributions and antimicrobial resistance (AMR) of bacteria causing UTI in men and to identify risk factors for resistance of <i>Escherichia coli</i> against trimethoprim (TMP) and ciprofloxacin (CIP).MethodsWe conducted a retrospective observational study using routinely collected midstream urine specimens from 102,736 adult male outpatients sent from 6,749 outpatient practices to nine collaborating laboratories from all major regions in Germany between 2015 and 2020. Resistance in <i>E. coli</i> was predicted using logistic regression.ResultsThe three most frequent bacteria were <i>E. coli</i> (38.4%), <i>Enterococcus faecalis</i> (16.5%) and <i>Proteus mirabilis</i> (9.3%). Resistance of <i>E. coli</i> against amoxicillin (45.7%), TMP (26.6%) and CIP (19.8%) was common. Multiple drug resistance was high (22.9%). Resistance against fosfomycin (0.9%) and nitrofurantoin (1.9%) was low. Resistance of <i>En. faecalis</i> against CIP was high (29.3%). Isolates of <i>P. mirabilis</i> revealed high resistance against TMP (41.3%) and CIP (16.6%). The CIP and TMP resistance was significantly higher among bacteria derived from recurrent UTI (p < 0.05). Age ≥ 90 years, recurrent UTI and regions East and South were independently associated with AMR of <i>E. coli</i> against TMP and CIP (p < 0.05).ConclusionThe most frequent UTI-causing pathogens showed highresistance against TMP and CIP, empirical therapy is therefore likely to fail. Apart from intrinsically resistant pathogens, susceptibility to fosfomycin and nitrofurantoin remains sufficient. Therefore, they remain an additional option for empirical treatment of uncomplicated UTI in men.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40644905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early start of seasonal transmission and co-circulation of West Nile virus lineage 2 and a newly introduced lineage 1 strain, northern Italy, June 2022.","authors":"Luisa Barzon,&nbsp;Fabrizio Montarsi,&nbsp;Erika Quaranta,&nbsp;Isabella Monne,&nbsp;Monia Pacenti,&nbsp;Alice Michelutti,&nbsp;Federica Toniolo,&nbsp;Patrizia Danesi,&nbsp;Giulio Marchetti,&nbsp;Federica Gobbo,&nbsp;Alessandro Sinigaglia,&nbsp;Silvia Riccetti,&nbsp;Emanuela Dal Molin,&nbsp;Laura Favero,&nbsp;Francesca Russo,&nbsp;Gioia Capelli","doi":"10.2807/1560-7917.ES.2022.27.29.2200548","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.29.2200548","url":null,"abstract":"<p><p>In spring 2022, Europe faced an unprecedented heatwave, increasing the risk of West Nile virus (WNV) outbreaks. As early as 7 June 2022, WNV was detected in <i>Culex</i> mosquitoes in northern Italy, and - in the following days - in two blood donors, a patient with encephalitis, wild birds and additional mosquito pools. Genome sequencing demonstrated co-circulation of WNV lineage 2 and a newly introduced WNV lineage 1, which was discovered in the region in 2021.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40528918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated use of laboratory services for multiple infectious diseases in the WHO European Region during the COVID-19 pandemic and beyond.","authors":"Daniel Simões, Soudeh Ehsani, Maja Stanojevic, Natalia Shubladze, Gulmira Kalmambetova, Roger Paredes, Daniela Maria Cirillo, Ana Avellon, Irina Felker, Florian P Maurer, Askar Yedilbayev, Francis Drobniewski, Lara Vojnov, Anne S Johansen, Nicole Seguy, Masoud Dara","doi":"10.2807/1560-7917.ES.2022.27.29.2100930","DOIUrl":"10.2807/1560-7917.ES.2022.27.29.2100930","url":null,"abstract":"<p><p>Technical advances in diagnostic techniques have permitted the possibility of multi-disease-based approaches for diagnosis and treatment monitoring of several infectious diseases, including tuberculosis (TB), human immunodeficiency virus (HIV), viral hepatitis and sexually transmitted infections (STI). However, in many countries, diagnosis and monitoring, as well as disease response programs, still operate as vertical systems, potentially causing delay in diagnosis and burden to patients and preventing the optimal use of available resources. With countries facing both human and financial resource constraints, during the COVID-19 pandemic even more than before, it is important that available resources are used as efficiently as possible, potential synergies are leveraged to maximise benefit for patients, continued provision of essential health services is ensured. For the infectious diseases, TB, HIV, hepatitis C (HCV) and STI, sharing devices and integrated services starting with rapid, quality-assured, and complete diagnostic services is beneficial for the continued development of adequate, efficient and effective treatment strategies. Here we explore the current and future potential (as well as some concerns), importance, implications and necessary implementation steps for the use of platforms for multi-disease testing for TB, HIV, HCV, STI and potentially other infectious diseases, including emerging pathogens, using the example of the COVID-19 pandemic.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40528919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned.","authors":"Jayshree Bagaria,&nbsp;Tessa Jansen,&nbsp;Diogo Fp Marques,&nbsp;Mariette Hooiveld,&nbsp;Jim McMenamin,&nbsp;Simon de Lusignan,&nbsp;Ana-Maria Vilcu,&nbsp;Adam Meijer,&nbsp;Ana-Paula Rodrigues,&nbsp;Mia Brytting,&nbsp;Clara Mazagatos,&nbsp;Jade Cogdale,&nbsp;Sylvie van der Werf,&nbsp;Frederika Dijkstra,&nbsp;Raquel Guiomar,&nbsp;Theresa Enkirch,&nbsp;Marta Valenciano","doi":"10.2807/1560-7917.ES.2022.27.26.2100864","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.26.2100864","url":null,"abstract":"<p><p>As the COVID-19 pandemic began in early 2020, primary care influenza sentinel surveillance networks within the Influenza - Monitoring Vaccine Effectiveness in Europe (I-MOVE) consortium rapidly adapted to COVID-19 surveillance. This study maps system adaptations and lessons learned about aligning influenza and COVID-19 surveillance following ECDC / WHO/Europe recommendations and preparing for other diseases possibly emerging in the future. Using a qualitative approach, we describe the adaptations of seven sentinel sites in five European Union countries and the United Kingdom during the first pandemic phase (March-September 2020). Adaptations to sentinel systems were substantial (2/7 sites), moderate (2/7) or minor (3/7 sites). Most adaptations encompassed patient referral and sample collection pathways, laboratory testing and data collection. Strengths included established networks of primary care providers, highly qualified testing laboratories and stakeholder commitments. One challenge was the decreasing number of samples due to altered patient pathways. Lessons learned included flexibility establishing new routines and new laboratory testing. To enable simultaneous sentinel surveillance of influenza and COVID-19, experiences of the sentinel sites and testing infrastructure should be considered. The contradicting aims of rapid case finding and contact tracing, which are needed for control during a pandemic and regular surveillance, should be carefully balanced.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40462677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of influenza vaccination in preventing influenza in primary care, Navarre, Spain, 2021/22.","authors":"Iván Martínez-Baz,&nbsp;Itziar Casado,&nbsp;Ana Miqueleiz,&nbsp;Ana Navascués,&nbsp;Francisco Pozo,&nbsp;Camino Trobajo-Sanmartín,&nbsp;Esther Albéniz,&nbsp;Fernando Elía,&nbsp;Cristina Burgui,&nbsp;Miguel Fernández-Huerta,&nbsp;Carmen Ezpeleta,&nbsp;Jesús Castilla","doi":"10.2807/1560-7917.ES.2022.27.26.2200488","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.26.2200488","url":null,"abstract":"<p><p>Compared with individuals unvaccinated in the current and three previous influenza seasons, in 2021/22, influenza vaccine effectiveness at primary care level was 37% (95% CI: 16 to 52) for current season vaccination, regardless of previous doses, and 35% (95% CI: -3 to 45) for only previous seasons vaccination. Against influenza A(H3N2), estimates were 39% (95% CI: 16 to 55) and 24% (95% CI: -8 to 47) suggesting moderate effectiveness of current season vaccination and possible remaining effect of prior vaccinations.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40462676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SARS-CoV-2 testing in patients with low COVID-19 suspicion at admission to a tertiary care hospital, Stockholm, Sweden, March to September 2020.","authors":"Ana Requena-Méndez,&nbsp;Aikaterini Mougkou,&nbsp;Pontus Hedberg,&nbsp;Suzanne D van der Werff,&nbsp;Hideyuki Tanushi,&nbsp;Olof Hertting,&nbsp;Anna Färnert,&nbsp;Filippa Nyberg,&nbsp;Pontus Naucler","doi":"10.2807/1560-7917.ES.2022.27.7.2100079","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.7.2100079","url":null,"abstract":"<p><p>BackgroundUniversal SARS-CoV-2 testing at hospital admission has been proposed to prevent nosocomial transmission.AimTo investigate SARS-CoV-2 positivity in patients tested with low clinical COVID-19 suspicion at hospital admission.MethodsWe characterised a retrospective cohort of patients admitted to Karolinska University Hospital tested for SARS-CoV-2 by PCR from March to September 2020, supplemented with an in-depth chart review (16 March-12 April). We compared positivity rates in patients with and without clinical COVID-19 suspicion with Spearman's rank correlation coefficient. We used multivariable logistic regression to identify factors associated with test positivity.ResultsFrom March to September 2020, 66.9% (24,245/36,249) admitted patient episodes were tested; of those, 61.2% (14,830/24,245) showed no clinical COVID-19 suspicion, and the positivity rate was 3.2% (469/14,830). There was a strong correlation of SARS-CoV-2 positivity in patients with low vs high COVID-19 suspicion (rho = 0.92; p < 0.001).From 16 March to 12 April, the positivity rate was 3.9% (58/1,482) in individuals with low COVID-19 suspicion, and 3.1% (35/1,114) in asymptomatic patients. Rates were higher in women (5.0%; 45/893) vs men (2.0%; 12/589; p = 0.003), but not significantly different if pregnant women were excluded (3.7% (21/566) vs 2.2% (12/589); p = 0.09). Factors associated with SARS-CoV-2 positivity were testing of pregnant women before delivery (odds ratio (OR): 2.6; 95% confidence interval (CI): 1.3-5.4) and isolated symptoms in adults (OR: 3.3; 95% CI: 1.8-6.3).ConclusionsThis study shows a relatively high SARS-CoV-2 positivity rate in patients with low COVID-19 suspicion upon hospital admission. Universal SARS-CoV-2 testing of pregnant women before delivery should be considered.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39640840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early chains of transmission of COVID-19 in France, January to March 2020.","authors":"Juliette Paireau,&nbsp;Alexandra Mailles,&nbsp;Catherine Eisenhauer,&nbsp;Franck de Laval,&nbsp;François Delon,&nbsp;Paolo Bosetti,&nbsp;Henrik Salje,&nbsp;Valérie Pontiès,&nbsp;Simon Cauchemez","doi":"10.2807/1560-7917.ES.2022.27.6.2001953","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.6.2001953","url":null,"abstract":"<p><p>IntroductionSARS-CoV-2, the virus that causes COVID-19, has spread rapidly worldwide. In January 2020, a surveillance system was implemented in France for early detection of cases and their contacts to help limit secondary transmissions.AimTo use contact-tracing data collected during the initial phase of the COVID-19 pandemic to better characterise SARS-CoV-2 transmission.MethodsWe analysed data collected during contact tracing and retrospective epidemiological investigations in France from 24 January to 30 March 2020. We assessed the secondary clinical attack rate and characterised the risk of a contact becoming a case. We described chains of transmission and estimated key parameters of spread.ResultsDuring the study period, 6,082 contacts of 735 confirmed cases were traced. The overall secondary clinical attack rate was 4.1% (95% confidence interval (CI): 3.6-4.6), increasing with age of index case and contact. Compared with co-workers/friends, family contacts were at higher risk of becoming cases (adjusted odds ratio (AOR): 2.1, 95% CI: 1.4-3.0) and nosocomial contacts were at lower risk (AOR: 0.3, 95% CI: 0.1-0.7). Of 328 infector/infectee pairs, 49% were family members. The distribution of secondary cases was highly over-dispersed: 80% of secondary cases were caused by 10% of cases. The mean serial interval was 5.1 days (interquartile range (IQR): 2-8 days) in contact tracing pairs, where late transmission events may be censored, and 6.8 (3-8) days in pairs investigated retrospectively.ConclusionThis study increases knowledge of SARS-CoV-2 transmission, including the importance of superspreading events during the onset of the pandemic.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39907053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk reduction of severe outcomes in vaccinated COVID-19 cases: an analysis of surveillance data from Estonia, Ireland, Luxembourg and Slovakia, January to November 2021.","authors":"Gaetano Marrone,&nbsp;Nathalie Nicolay,&nbsp;Nick Bundle,&nbsp;Tommi Karki,&nbsp;Gianfranco Spiteri,&nbsp;Heleene Suija,&nbsp;Kerstin-Gertrud Kärblane,&nbsp;Joël Mossong,&nbsp;Anne Vergison,&nbsp;Maria Avdicova,&nbsp;Adriana Mecochova,&nbsp;Gillian Cullen,&nbsp;Piaras O'Lorcain,&nbsp;Lucia Pastore Celentano,&nbsp;Tarik Derrough,&nbsp;Julien Beauté","doi":"10.2807/1560-7917.ES.2022.27.7.2200060","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.7.2200060","url":null,"abstract":"<p><p>Despite high COVID-19 vaccine coverage in the EU/EEA, there are increasing reports of SARS-CoV-2 infections and hospitalisations in vaccinated individuals. Using surveillance data from Estonia, Ireland, Luxembourg and Slovakia (January-November 2021), we estimated risk reduction of severe outcomes in vaccinated cases. Increasing age remains the most important driver of severity, and vaccination significantly reduces risk in all ages for hospitalisation (adjusted relative risk (aRR): 0.32; 95% confidence interval (CI): 0.26-0.39) and death (aRR: 0.20; 95% CI: 0.13-0.29).</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39640838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From more testing to smart testing: data-guided SARS-CoV-2 testing choices, the Netherlands, May to September 2020.","authors":"Janko van Beek,&nbsp;Zsofia Igloi,&nbsp;Timo Boelsums,&nbsp;Ewout Fanoy,&nbsp;Hannelore Gotz,&nbsp;Richard Molenkamp,&nbsp;Jeroen van Kampen,&nbsp;Corine GeurtsvanKessel,&nbsp;Annemiek A van der Eijk,&nbsp;David van de Vijver,&nbsp;Marion Koopmans","doi":"10.2807/1560-7917.ES.2022.27.8.2100702","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2022.27.8.2100702","url":null,"abstract":"<p><p>BackgroundSARS-CoV-2 RT-PCR assays are more sensitive than rapid antigen detection assays (RDT) and can detect viral RNA even after an individual is no longer infectious. RDT can reduce the time to test and the results might better correlate with infectiousness.AimWe assessed the ability of five RDT to identify infectious COVID-19 cases and systematically recorded the turnaround time of RT-PCR testing.MethodsSensitivity of RDT was determined using a serially diluted SARS-CoV-2 stock with known viral RNA concentration. The probability of detecting infectious virus at a given viral load was calculated using logistic regression of viral RNA concentration and matched culture results of 78 specimens from randomly selected non-hospitalised cases. The probability of each RDT to detect infectious cases was calculated as the sum of the projected probabilities for viral isolation success for every viral RNA load found at the time of diagnosis in 1,739 confirmed non-hospitalised COVID-19 cases.ResultsThe distribution of quantification cycle values and estimated RNA loads for patients reporting to drive-through testing was skewed to high RNA loads. With the most sensitive RDT (Abbott and SD Biosensor), 97.30% (range: 88.65-99.77) of infectious individuals would be detected. This decreased to 92.73% (range: 60.30-99.77) for Coris BioConcept and GenBody, and 75.53% (range: 17.55-99.77) for RapiGEN. Only 32.9% of RT-PCR results were available on the same day as specimen collection.ConclusionThe most sensitive RDT detected infectious COVID-19 cases with high sensitivity and may considerably improve containment through more rapid isolation and contact tracing.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39958680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author's correction for Euro Surveill. 2022;27(3).","authors":"","doi":"10.2807/1560-7917.ES.2021.27.6.210310c","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2021.27.6.210310c","url":null,"abstract":"","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39907052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}